Mark Lebwohl Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

05/2008	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
05/2008	Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
03/2008	The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
04/2007	Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
02/2007	A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
10/2006	A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.
01/2006	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
12/2005	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
09/2005	Proven efficacy of tacrolimus for facial and intertriginous psoriasis.
07/2005	An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
11/2004	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
11/2004	Tacrolimus ointment is effective for facial and intertriginous psoriasis.
04/2004	Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
11/2003	A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
06/2003	An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
04/2003	Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
03/2003	Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
05/2002	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.

Articles by Research Topic

Disease

18	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2008 - 05/2002
4	Atopic Dermatitis (Atopic Eczema) 01/2006 - 04/2003
2	Neoplasms (Cancer) 03/2008 - 08/2005
2	Vitiligo 06/2006 - 07/2004
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2005 - 04/2003
2	Keratosis 05/2004 - 10/2002
1	Skin Diseases 06/2008
1	Skin Neoplasms (Skin Cancer) 04/2006
1	Necrobiosis Lipoidica 03/2006
1	Rheumatoid Arthritis 07/2005
1	Seborrheic Dermatitis 07/2004
1	Dermatitis 04/2004
1	Pseudoxanthoma Elasticum (Gronblad Strandberg Syndrome) 11/2003
1	Infection 06/2003
1	DNA Damage 04/2003
1	Mycosis Fungoides 09/2002
1	Acne Vulgaris 04/2002

Drug/Important Bio-Agent (IBA)

6	Tacrolimus (Prograf)FDA Link 09/2005 - 04/2003
4	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 06/2008 - 05/2002
4	Benzo(a)pyreneIBA 03/2008 - 04/2003
4	alefacept (Amevive)FDA Link 01/2006 - 03/2003
2	Interleukin-12 (IL 12)IBA 05/2008 - 02/2007
2	RetinoidsIBA 05/2008 - 04/2006
2	TNFR-Fc fusion protein (etanercept)FDA Link 03/2006 - 07/2005
2	efalizumab FDA Link 12/2005 - 11/2003
2	pimecrolimus (Elidel)FDA Link 05/2005 - 11/2004
2	imiquimod (Aldara)FDA Link 05/2004 - 10/2002
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2003 - 04/2003
1	Fluocinonide (Lidex)FDA LinkGeneric 06/2008
1	Calcitriol (Calcijex)FDA LinkGeneric 04/2007
1	calcipotriene (calcipotriol)FDA LinkGeneric 10/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2006
1	CalcineurinIBA 01/2006
1	ciclopirox (Loprox)FDA LinkGeneric 07/2004
1	galiximabIBA 04/2004
1	CollagenIBA 11/2003
1	bexarotene (LGD1069)FDA Link 09/2002
1	tazarotene (Tazorac)FDA Link 04/2002

Therapy/Procedure

2	Excimer Lasers 06/2006 - 07/2004
1	Biological Therapy 03/2008
1	Chemoprevention 04/2006